Gilead Sciences: Strong Long-Term Growth At A Bargain

... of Pharmasset in 2011. Gilead has a strong portfolio of drugs that is primarily focused on treatments for HIV/AIDS and Hepatitis C, along with a few other miscellaneous drugs. For HIV/AIDS, the company's current main drug is Atripla, which was ...

http://ift.tt/1mvybJV